BIOBANK MARKET ANALYSIS

Leading Companies

Development of personalized medicine to develop effective therapies drives the global biobank market

Poor productivity rate of the pharmaceutical industry with 90% failure of proposed drugs during clinical trials, the adherence of human tissue samples, and stem cells to execute pre-clinical trials for reducing high cost associated drug failures are the factors expected to drive the growth of biobank market. Additionally, novelty in cell and tissue disorder treatments, drug discovery, rising incidence of chronic diseases and government initiatives for innovation of regenerative medicines are the key factors driving the global biobank market. The extensive development of personalized treatments by research organizations to develop effective therapies to satisfy medical needs using biological samples is expected to fuel the demand for biobank market during the forecast period. For instance, Illumina signed 4 biobank deals in 2016, with Partners HealthCare, Montreal Heart Institute, University of Colorado and Vanderbilt University with an objective to improve healthcare and develop personalized medicines. However, cost competitive techniques, tissue injury during freezing, reimbursement concerns, lack of standardization, confidentiality and surveillance issues, economic downturn, and ethical issues are the major factors restraining the growth for global biobank market.

Increasing funds from National Institute of Health, USA is expected to dominate North America in the global biobank market

Regional segmentation of the global biobank market by Coherent Market Insights comprises North America, Latin America, Europe, and Asia-Pacific. According to the research conducted by BioMed Central, United States, stored 270 million specimens in biobanks in 2008, with the rate of new samples collected being 20 million every year. North America is expected to dominate the global biobank market with the increasing funds from healthcare organizations like National Institute of Health (NIH) and National Cancer Institute, which facilitate biobanks across the U.S. in October 2017, National Institutes of Health granted $2.1 million to the UK ME/CFS Biobank, which represents a huge investment in biomedical research. Thus, rise in funds for biobanks is expected to fuel the biobanking market size. Additionally, the rising interest in biotechology has facilitated collaborations of biobanks which is expected to augment the global biobank market in the forecast period. Asia-Pacific is expected to have an opportunistic biobank market owing to the rise in diseases, government initiative to finance the cell-based therapies, substantial investment by pharmaceutical, high number of biotechnology companies, and public awareness.